Eli Lilly and Company (LLY) — closed signal from April 4, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 3, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$920.00 – $945.00Entry zone — fair-value band
$935.58Published — price the day we called it
$1,113.34Target — the price the thesis aimed for
$1,238.00Peak — highest point inside the window, not a realized return
$1,213.91Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 54 days.
Peak price
$1,238.00
peak on June 29, 2026 — not a realized returnPeak gain
+32.3%
peak, from the publication priceWindow close
$1,213.91
end-of-window price, context onlyDays to target
54
Window
April 4, 2026 – July 3, 2026
The thesis — published April 4, 2026
Predicted growth
+19%
over the measurement windowTarget price
$1,113.34
the price the thesis aimed forEntry zone
$920.00 – $945.00
the fair-value band we waited forPrice at publication
$935.58
published April 4, 2026Confidence
83%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly just got FDA approval for a once-daily oral obesity drug, Foundayo. That approval could prompt analysts to raise sales and profit forecasts and strengthen Lilly's lead in a growing market for weight treatments. The stock is trading near short-term support and shows steady momentum, making the current setup more appealing than many post-approval moves.
Primary drivers
- Foundayo approval widens the market for an oral obesity medicine
- Strong diabetes and obesity franchises give steady revenue support
- Recent earnings helped push forecasts higher
- Stock sits near short-term support with steady momentum
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.